Novo Nordisk has announced the investment of more than $2.3 billion to expand its existing production site in Chartres, France, for its current and future portfolio of products for the treatment of serious chronic diseases. The investment will add aseptic production and finished production processes, as well as capacity for GLP-1 products and an extension of the current Quality Control Laboratory.
The new facility will be designed as a multi-product site to accommodate current and future processes with state-of-the-art technology. Construction has been initiated and will gradually be finalized from 2026 to 2028. It will focus on delivering the highest quality to patients globally in an efficient and environmentally sustainable way.
The investment is expected to create more than 500 new jobs to run production activities 24/7 when the construction is completed, and the facilities are finalized. During the construction phase, up to 2,000 external individuals will be employed.
“This significant investment confirms the importance of our French manufacturing site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company,” says Lone Charlotte Larsen, corporate vice president of Novo Nordisk production Chartres. “By maximizing the skills and infrastructure we already have on the site, we are expanding our capacity in an efficient way.”
“Our continued investments in our manufacturing sites across the globe demonstrate the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases,” states Henrik Wulff, executive vice president, product supply, quality & IT, Novo Nordisk.
